Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Slides:

Advertisements

Similar presentations

Impact of Diabetes Mellitus on Early and Long-term Results of Percutaneous Drug- eluting Stent Implantation for Unprotected Left Main Coronary Disease.

Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Can we prevent stent restenosis after coronary stent implantation

ARTS I & II Keith D Dawkins Southampton University Hospital.

Arterial Revascularization Therapies Part II: a nonrandomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

Copyright © 2014 American Medical Association. All rights reserved.

Figure 1 Flow diagram of systematic review

From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Figure 1 Ischaemic endpoints

Figure 1 A flow chart describing the systematic process followed for article selection. From: A systematic review of cost-effectiveness of percutaneous.

From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Robert A. Guyton, MD The Annals of Thoracic Surgery

Copyright © 2013 American Medical Association. All rights reserved.

Figure 1 Flow chart diagram of high-risk group AF patients

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Figure 1 Flow chart of study selection.

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Presented by Dr. Leif Thuesen

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Glenn N. Levine et al. JACC 2016;68:

Giuseppe Biondi Zoccai

Robert A. Guyton, MD The Annals of Thoracic Surgery

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

European Society of Cardiology 2003

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Maintenance of Long-Term Clinical Benefit with

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.

Stent Versus Off-Pump Coronary Bypass Grafting in the Second-Generation Drug- Eluting Stent Era Gijong Yi, MD, PhD, Hyun-Chel Joo, MD, Young-Nam Youn,

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

The American College of Cardiology Presented by Dr. A. Abazid

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization Paul Kurlansky, MD, Morley Herbert, PhD, Syma.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have been eligible for inclusion in randomized controlled trials (RCT) in the pre-SES and SES era, and (B) would have been eligible for inclusion in randomized controlled trials in the pre-SES and SES era. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have been eligible for inclusion in randomized controlled trials (RCT) in the pre-SES and SES era, and (B) would have been eligible for inclusion in randomized controlled trials in the pre-SES and SES era. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 2 (A) Cumulative revascularization percentages, and (B) cumulative one-year adverse events (death, post-discharge myocardial infarction, revascularization) after CABG and PCI according to the bare-stent (implantation of a bare metal stent in the pre-SES period), pure-stent [only SES(s) implanted without bare metal stents], pre-SES CABG and SES CABG. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 2 (A) Cumulative revascularization percentages, and (B) cumulative one-year adverse events (death, post-discharge myocardial infarction, revascularization) after CABG and PCI according to the bare-stent (implantation of a bare metal stent in the pre-SES period), pure-stent [only SES(s) implanted without bare metal stents], pre-SES CABG and SES CABG. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 1 (A) Cumulative death and post-discharge myocardial infarction percentages; (B) cumulative revascularization; and (C) cumulative major adverse cardiac events (death, post-discharge myocardial infarction, revascularization) after revascularization (PCI and CABG combined) according to the pre-SES and SES era 12 months after the index procedure. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 1 (A) Cumulative death and post-discharge myocardial infarction percentages; (B) cumulative revascularization; and (C) cumulative major adverse cardiac events (death, post-discharge myocardial infarction, revascularization) after revascularization (PCI and CABG combined) according to the pre-SES and SES era 12 months after the index procedure. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Figure 1 (A) Cumulative death and post-discharge myocardial infarction percentages; (B) cumulative revascularization; and (C) cumulative major adverse cardiac events (death, post-discharge myocardial infarction, revascularization) after revascularization (PCI and CABG combined) according to the pre-SES and SES era 12 months after the index procedure. From: The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease Eur Heart J. 2005;26(7):675-681. doi:10.1093/eurheartj/ehi088 Eur Heart J | © The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org